Public research preview
Julia Letlow, Representative disclosure: 1) Accenture plc Class A Ordinary Shares (ACN)
Disclosed a buy transaction in 1) Accenture plc Class A Ordinary Shares (ACN). Use this page to inspect source evidence, confidence scores, filing delay, and post-disclosure price movement before deciding whether to research the signal further.
This public page is for public-disclosure research only. It is not investment advice and does not place orders. Verify the official source before relying on any signal.
Evidence passport
Official-source context and parser confidence before any simulation or alert decision.
- Source
- House STOCK Act disclosures
- Published
- 13 Jan 2026, 00.00
- Parser confidence
- 94%
- Instrument mapping
- 95%
- Filing delay
- 447 days
Timeline
Transaction date
23 Oct 2024
Public disclosure
13 Jan 2026
Now
Tracked today
Filing delay: 447 days
Price movement
Complete coverage
- Provider
- Yahoo Finance daily close
- Fetched
- 12 Jun 2026
Stock path
ACN from pre-transaction context through latest close.
Bought
23 Oct 2024 · 362,34 USD · Not public yet
System decision
Would not buy — The strategy's filters reject this signal. Failed filters: Filed within 30 days.
- Not public yet
- Would not buy
- Observed transaction close
- 362,34
- Observed disclosure close
- 274,472
- Observed latest close
- 167,52
- Pre-disclosure move
- -24.3%
- Post-disclosure move
- -39.0%
- Market-adjusted move
- -45.6%
- Pre-disclosure peak run-up
- +7.9%
- Retrace from peak
- -29.8%
Why Copy Window is Probably too late
Supporting factors
- Parsed buy disclosure for ordinary shares from House STOCK Act disclosures.
- Reported amount is $1,001 - $15,000.
- Post-disclosure move is calculated from Yahoo Finance daily close daily closes.
Cautions
- Yahoo Finance daily close coverage is end-of-day and should be verified against the official price source.
- Review the original source document before making any investment decision.
Source document
House STOCK Act disclosures, published 13 Jan 2026, 00.00
- Parser confidence
- 94%
- Instrument mapping
- 95%